The amino terminus of Cdk2 binds p21.
The cyclin-dependent kinase (Cdk) inhibitor known as p21, which is transcriptionally regulated by p53, can induce G1 arrest when overexpressed and inhibit the kinase activity of a wide variety of cyclin-Cdk complexes. Previous studies have demonstrated that a portion of the conserved region of p21 (amino acids 46-78), which is homologous to similar regions in the related Cdk inhibitors p27 and p57, can bind to Cdk2, and that this region is essential for kinase inhibition. However, the site(s) on Cdk2 that are involved in p21 binding have not been identified. We therefore created mutant Cdk2 molecules with various N-terminal and C-terminal deletions and tested each for their ability to bind to p21 by the yeast two-hybrid and the double-tagging assays. None of the deletion mutants tested bound to p21 by either assay. We next tested whether p21 could bind to Cdk7, a component of the cyclin-activating kinase complex. By both the double-tagging and yeast two-hybrid assays, p21 failed to bind to this protein, consistent with previous reports. However, hybrid molecules consisting of the amino-terminal half of Cdk2 and the carboxy-terminal half of Cdk7 (Cdk2/Cdk7) could bind to p21 by both assays, whereas the Cdk7/Cdk2 hybrids could not. Furthermore, the yeast Cdc28 protein, which is 65% identical with Cdk2, failed to bind to p21 by both the yeast two-hybrid and double-tagging assays. Cdk2/Cdc28 hybrids but not Cdc28/Cdk2 hybrids could bind to p21. These results suggest that the amino-terminal half of Cdk2 is important for p21 binding, consistent with the recently published crystal-lographic data. Our data also suggest that the three-dimensional structure of Cdk2 is likely altered by creating deletion mutants from either the amino- or carboxy-terminal end of the protein. Finally, we have mutated the Cdc28/Cdk2 hybrid protein and isolated several mutants, which are able to bind to p21. This approach may be useful for identifying residues in Cdk2 and Cdc28 that affect their ability to bind to p21 and complement the crystallographic data.
Moskowitz
N K
NK
University of Medicine and Dentistry of New Jersey, Cancer Institute of New Jersey, New Brunswick 08901, USA.
Borao
F J
FJ
Dardashti
O
O
Cohen
H D
HD
Germino
F J
FJ
D000595:Amino Acid Sequence; D001665:Binding Sites; D042846:CDC2-CDC28 Kinases; D017489:CDC28 Protein Kinase, S cerevisiae / Q000378:metabolism*; D002874:Chromosome Mapping; D051357:Cyclin-Dependent Kinase 2; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D016213:Cyclins / Q000378:metabolism*; D004252:DNA Mutational Analysis; D008969:Molecular Sequence Data; D017346:Protein Serine-Threonine Kinases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000378:metabolism*; D000095043:Cyclin-Dependent Kinase-Activating Kinase
D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D011993:Recombinant Fusion Proteins; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; D017489:CDC28 Protein Kinase, S cerevisiae; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases; D000095043:Cyclin-Dependent Kinase-Activating Kinase